Compare NEULAND LABS with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS FULFORD INDIA NEULAND LABS/
FULFORD INDIA
 
P/E (TTM) x 50.5 398.8 12.7% View Chart
P/BV x 3.8 6.2 61.5% View Chart
Dividend Yield % 0.1 0.1 111.6%  

Financials

 NEULAND LABS   FULFORD INDIA
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
FULFORD INDIA
Mar-14
NEULAND LABS/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs754942 80.0%   
Low Rs247450 55.0%   
Sales per share (Unadj.) Rs594.5691.4 86.0%  
Earnings per share (Unadj.) Rs12.611.5 110.2%  
Cash flow per share (Unadj.) Rs37.015.4 241.0%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.40.3 139.1%  
Book value per share (Unadj.) Rs553.4380.0 145.6%  
Shares outstanding (eoy) m12.833.90 329.0%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.81.0 83.6%   
Avg P/E ratio x39.660.7 65.2%  
P/CF ratio (eoy) x13.545.3 29.8%  
Price / Book Value ratio x0.91.8 49.4%  
Dividend payout %15.817.4 90.7%   
Avg Mkt Cap Rs m6,4212,714 236.5%   
No. of employees `0001.30.4 288.7%   
Total wages/salary Rs m1,236505 244.7%   
Avg. sales/employee Rs Th5,949.46,073.0 98.0%   
Avg. wages/employee Rs Th963.81,137.4 84.7%   
Avg. net profit/employee Rs Th126.4100.7 125.6%   
INCOME DATA
Net Sales Rs m7,6272,696 282.9%  
Other income Rs m39125 31.0%   
Total revenues Rs m7,6662,822 271.7%   
Gross profit Rs m1,019-46 -2,195.9%  
Depreciation Rs m31315 2,057.9%   
Interest Rs m21610 2,270.8%   
Profit before tax Rs m52954 974.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m36710 3,824.2%   
Profit after tax Rs m16245 362.6%  
Gross profit margin %13.4-1.7 -776.3%  
Effective tax rate %69.417.7 392.4%   
Net profit margin %2.11.7 128.2%  
BALANCE SHEET DATA
Current assets Rs m5,1521,738 296.4%   
Current liabilities Rs m3,576545 656.6%   
Net working cap to sales %20.744.3 46.7%  
Current ratio x1.43.2 45.1%  
Inventory Days Days10548 216.8%  
Debtors Days Days914 2,111.0%  
Net fixed assets Rs m3,96912 33,348.9%   
Share capital Rs m12939 330.8%   
"Free" reserves Rs m6,9711,443 483.1%   
Net worth Rs m7,1001,482 479.1%   
Long term debt Rs m7740-   
Total assets Rs m12,3102,077 592.8%  
Interest coverage x3.56.7 51.4%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.3 47.7%   
Return on assets %3.12.6 117.6%  
Return on equity %2.33.0 75.7%  
Return on capital %9.54.3 219.8%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m5,18717 30,155.2%   
Fx outflow Rs m1,593673 236.6%   
Net fx Rs m3,594-656 -547.9%   
CASH FLOW
From Operations Rs m57390 637.1%  
From Investments Rs m-487105 -465.4%  
From Financial Activity Rs m-55-14 388.7%  
Net Cashflow Rs m33181 18.1%  

Share Holding

Indian Promoters % 36.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 63.7 3.8 1,677.1%  
FIIs % 0.0 0.1 -  
ADR/GDR % 0.0 0.0 -  
Free float % 63.7 21.2 300.6%  
Shareholders   12,705 4,783 265.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT PHARMOVA   

Compare NEULAND LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Bharti Airtel Q4 Performance, Spot Gold Exchange Framework, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a strong note yesterday. Benchmark indices continued their positive momentum for the second consecutive day.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NEULAND LABS SHARE PRICE


May 18, 2021 (Close)

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NEULAND LABS 8-QTR ANALYSIS

COMPARE NEULAND LABS WITH

MARKET STATS